Serum levels of β-hydroxybutyrate and pyruvate, metabolic changes and cognitive function in patients with schizophrenia during antipsychotic treatment: a preliminary study

Amino acids and acylcarnitines play an important role as substrates and intermediate products in most of pathways involved in schizophrenia development such as mitochondrial dysfunction, inflammation, lipid oxidation, DNA damage, oxidative stress, and apoptosis. It seems relevant to use an integrated approach with ‘omics’ technology to study their contribution. The aim of our study was to investigate serum amino acid and acylcarnitine levels in antipsychotics-treated patients with chronic schizophrenia compared with healthy donors. We measured serum levels of 15 amino acids and 30 acylcarnitines in 37 patients with schizophrenia and 36 healthy donors by means of tandem mass spectrometry. In summary, patients with chronic schizophrenia had an altered concentration of a few amino acids and acylcarnitines in comparison to the healthy probands. Further research is needed to assess and understand the identified changes.

Download Full-text

Relationship between blood pressure, cognitive function and education level in elderly patients with diabetes: A preliminary study

Diabetes & Metabolism ◽

10.1016/j.diabet.2013.02.008 ◽

2013 ◽

Vol 39 (5) ◽

pp. 418-423 ◽

Cited By ~ 3

Author(s):

J. Talfournier ◽

J. Bitu ◽

C. Paquet ◽

C. Gobron ◽

P.J. Guillausseau ◽

...

Keyword(s):

Blood Pressure ◽

Cognitive Function ◽

Elderly Patients ◽

Education Level ◽

Patients With Diabetes ◽

Preliminary Study

Download Full-text

Effects of Playback Theatre on cognitive function and quality of life in older adults in Singapore: A preliminary study

Australasian Journal on Ageing ◽

10.1111/ajag.12498 ◽

2018 ◽

Vol 37 (1) ◽

pp. E33-E36 ◽

Cited By ~ 2

Author(s):

Krystal Shu Yi Chung ◽

Eleena Shi Lynn Lee ◽

Jia Qi Tan ◽

Dylan Jin Hao Teo ◽

Chris Ban Loong Lee ◽

...

Keyword(s):

Quality Of Life ◽

Older Adults ◽

Cognitive Function ◽

Playback Theatre ◽

Preliminary Study

Download Full-text

Long-term physical activity modulates adipsin and ANGPTL4 serum levels, a potential link to exercise-induced metabolic changes

Panminerva Medica ◽

10.23736/s0031-0808.21.04382-2 ◽

2021 ◽

Author(s):

Max LENZ ◽

Robert SCHÖNBAUER ◽

Stefan STOJKOVIC ◽

Michael LICHTENAUER ◽

Vera PAAR ◽

...

Keyword(s):

Physical Activity ◽

Serum Levels ◽

Metabolic Changes ◽

Potential Link ◽

Exercise Induced

Download Full-text

The association between dual-task walking and counting responses and cognitive function and disability after severe head injury: A preliminary study

Neuropsychological Rehabilitation ◽

10.1080/09602011.2020.1716812 ◽

2020 ◽

pp. 1-13

Author(s):

Linda M. Maclean ◽

Paula McSkimming ◽

Tom M. McMillan

Keyword(s):

Cognitive Function ◽

Head Injury ◽

Dual Task ◽

Severe Head Injury ◽

Preliminary Study

Download Full-text

MMP-7 and fcDNA Serum Levels in Early NSCLC and Idiopathic Interstitial Pneumonia: Preliminary Study

International Journal of Molecular Sciences ◽

10.3390/ijms141224097 ◽

2013 ◽

Vol 14 (12) ◽

pp. 24097-24112 ◽

Cited By ~ 10

Author(s):

Paola Ulivi ◽

Gian Casoni ◽

Giovanni Foschi ◽

Emanuela Scarpi ◽

Sara Tomassetti ◽

...

Keyword(s):

Interstitial Pneumonia ◽

Serum Levels ◽

Idiopathic Interstitial Pneumonia ◽

Preliminary Study

Download Full-text

Changes in the cytokine profile in first episode, drug-naïve patients with psychosis after short-term antipsychotic treatment

European Psychiatry ◽

10.1016/j.eurpsy.2017.02.382 ◽

2017 ◽

Vol 41 (S1) ◽

pp. S371-S371

Author(s):

P. Petrikis ◽

P. Voulgari ◽

V. Boumba ◽

D. Archimandriti ◽

P. Skapinakis ◽

...

Keyword(s):

Antipsychotic Medication ◽

Transforming Growth Factor ◽

Serum Levels ◽

Psychotic Symptoms ◽

First Episode ◽

Enzyme Linked Immunosorbent Assay ◽

Antipsychotic Treatment ◽

Before And After ◽

Drug Naïve ◽

Competing Interest

IntroductionAn increasing body of evidence suggests that antipsychotic medication can cause immunological changes that could be attributed to the amelioration of psychotic symptoms or the metabolic side effects of the drugs. So far, the results of the studies remain controversial.ObjectiveOur aim was to compare the levels of interleukin (IL) IL-2, IL-6 and transforming growth factor-β2 (TGF-β2) in drug-naïve, first-episode patients with psychosis before and after six weeks of antipsychotic medication.MethodsThirty-nine first episode patients with psychosis were enrolled in the study. Serum levels of IL-2, IL-6 and TGF-β2 were measured by enzyme linked immunosorbent assay (ELISA) before and six weeks after the initiation of antipsychotic medication. In addition, clinical psychopathology was assessed using Positive and Negative Syndrome Scale (PANSS) before and after treatment.ResultsSerum levels of IL-2 were significantly higher in the study group six weeks after the initiation of antipsychotic treatment (P < 0.001) while TGF-β2 levels were decreased (P < 0.001) and IL-6 levels were slightly reduced (P < 0.004).ConclusionThe changes in cytokine levels may be attributed to the action of antipsychotic medication and the remission of psychopathology. The reduction in TGF-β2 levels is observed in all patients and with all antipsychotic medications used. TGF-β2 may be a marker of clinical efficacy.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Download Full-text

BDNF and S100B in psychotic disorders: evidence for an association with treatment responsiveness

Acta Neuropsychiatrica ◽

10.1017/neu.2013.59 ◽

2013 ◽

Vol 26 (4) ◽

pp. 223-229 ◽

Cited By ~ 3

Author(s):

Noortje W.A. van de Kerkhof ◽

Durk Fekkes ◽

Frank M.M.A. van der Heijden ◽

Willem M.A. Verhoeven

Keyword(s):

Negative Symptoms ◽

Psychotic Disorders ◽

Brain Plasticity ◽

Control Sample ◽

Serum Levels ◽

Response To Treatment ◽

Antipsychotic Treatment ◽

Specific Symptom ◽

Symptom Dimensions ◽

Symptom Profile

ObjectiveBrain-derived neurotrophic factor (BDNF) and S100B are involved in brain plasticity processes and their serum levels have been demonstrated to be altered in patients with psychoses. This study aimed to identify subgroups of patients with psychotic disorders across diagnostic boundaries that show a specific symptom profile or response to treatment with antipsychotics, by measuring serum levels of BDNF and S100B.MethodsThe study sample consisted of 58 patients with DSM-IV psychotic disorders. Comprehensive Assessment of Symptoms and History (CASH), Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression scale for severity and improvement (CGI-S/CGI-I) were applied at baseline and after 6 weeks of antipsychotic treatment. At both time points, serum levels of BDNF and S100B were measured and compared with a matched control sample.ResultsBaseline BDNF and S100B levels were significantly lower in patients as compared with controls and did not change significantly during treatment. Dividing the patient sample according to baseline biochemical parameters (low and high 25% and middle 50%), no differences in symptom profiles or outcome were found with respect to BDNF. However, the subgroups with low and high S100B levels had higher PANSS scores than the middle subgroup. In addition, the high subgroup still showed significantly more negative symptoms after treatment, whereas the low subgroup showed more positive symptoms compared with the other subgroups.ConclusionSerum levels of BDNF and S100B are lowered in patients with psychotic disorders across diagnostic boundaries. The differences between high and low S100B subgroups suggest a relationship between S100B, symptom dimensions and treatment response, irrespective of diagnostic categories.

Download Full-text